• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Teddy Rosenbluth
Author: Teddy Rosenbluth

Written by

Teddy Rosenbluth

in

Cassava Sciences Inc, Clinical Trials, Decisions and Verdicts, Falsification of Data, Regulation and Deregulation of Industry, Research, Securities and Commodities Violations, simufilam
←At the Brooklyn Academy, Musical Journeys Through Minefields
EV Projects to Get $13 Billion in Federal Loans→

More posts

  • Rihanna’s Beverly Hills home hit by gunfire; suspect arrested, LAPD says

  • Tommy DeCarlo, Boston fan who became the band’s lead singer, dies at 60

  • Trump is delaying Texas Senate endorsement to pressure GOP senators on SAVE America Act

  • New video appears to show U.S. tomahawk missile hitting near school in Iran

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube